- Drugs Made In America Acquisition II Corp. (DMII) priced its initial public offering of **50,000,000 units** at **$10.00 per unit** on September 25, 2025.  **[2040475_0001213900-25-093224_ea025896901ex99-1_drugs2.htm:0]** 
- The IPO closed on September 26, 2025, generating **$500,000,000** in gross proceeds before deducting underwriting discounts and offering expenses.  **[2040475_0001213900-25-093224_ea025896901ex99-2_drugs2.htm:0]** **[2040475_0001213900-25-093224_ea0258969-8k_drugs2.htm:1]** 
- Concurrently with the IPO closing, the company closed a private placement of **1,200,000 private placement units** at **$10.00 per unit**, resulting in gross proceeds of **$12,000,000**.  **[2040475_0001213900-25-093224_ea025896901ex99-2_drugs2.htm:0]** 
- A total of **$500,000,000** from the proceeds of the initial public offering and the private placement has been deposited into a trust account.  **[2040475_0001213900-25-093224_ea025896901ex99-2_drugs2.htm:0]** **[2040475_0001213900-25-093224_ea0258969-8k_drugs2.htm:1]** 
- The units began trading on The Nasdaq Global Market under the ticker symbol **DMIIU** on September 25, 2025.  **[2040475_0001213900-25-093224_ea025896901ex99-2_drugs2.htm:0]** **[2040475_0001213900-25-093224_ea025896901ex99-1_drugs2.htm:0]**

Drugs Made In America Acquisition II (DMII)